Table of contents
April 2006 Vol 5 No 4
In This Issue
p265 | doi:10.1038/nrd2024
Editorial: Common ground on the critical path
p267 | doi:10.1038/nrd2019
News and Analysis
Controversial Chinese gene-therapy drug entering unfamiliar territory | PDF (279 KB)
p269 | doi:10.1038/nrd2017
Funding for accelerating drug development initiative critical | PDF (65 KB)
p271 | doi:10.1038/nrd2015
News in Brief
Patent watch
Paxil: part of the process | Friends in high places | PDF (66 KB)
p274 | doi:10.1038/nrd2025
Patent primer
Grace periods and patentability | PDF (57 KB)
p275 | doi:10.1038/nrd2010
An Audience With
Sir Michael Rawlins | PDF (62 KB)
p276 | doi:10.1038/nrd2016
From the analyst's couch
The GERD market | PDF (223 KB)
p277 | doi:10.1038/nrd2011
Fresh from the Pipeline
Sunitinib maleate | PDF (149 KB)
p279 | doi:10.1038/nrd2012
Research Highlights
High-throughput screening: Parallel lines | PDF (299 KB)
p281 | doi:10.1038/nrd2013
Antiviral drugs: Probing viral assembly | PDF (399 KB)
p282 | doi:10.1038/nrd2014
Anticancer drugs: Targeting resistance | PDF (399 KB)
p282 | doi:10.1038/nrd2020
In brief
Kinase inhibitors | Osteoporosis | Gene therapy | Neurological disorders | PDF (101 KB)
p283 | doi:10.1038/nrd2021
Antibacterial drugs: Pinpoint attack on resistance | PDF (101 KB)
p284 | doi:10.1038/nrd2022
Psychiatric disorders: Simulating schizophrenia | PDF (115 KB)
p284 | doi:10.1038/nrd2023
Perspectives
Outlook
Entry order as a consideration for innovation strategies
Fredric J. Cohen
p285 | doi:10.1038/nrd2009
Prior studies have suggested that late market entrants within a drug class frequently outperform first entrants. This idea and the general relationship between entry order and quality attributes are explored by Cohen, with a focus on the implications for innovation strategies.
Reviews
Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy
Scott M. Grundy
p295 | doi:10.1038/nrd2005
The metabolic syndrome — a collection of factors associated with increased risk for cardiovascular disease and diabetes — is becoming increasingly common. Grundy summarizes the current understanding of the nature of the metabolic syndrome, and discusses each of the risk factors of the metabolic syndrome as possible drug targets.
Multiplexed protein measurement: technologies and applications of protein and antibody arrays
Stephen F. Kingsmore
p310 | doi:10.1038/nrd2006
Multiplexed protein measurement is being established in applications such as comprehensive proteomic surveys, validation of genomic discoveries and clinical biomarker development. Kingsmore describes current and emerging multiplexed protein-measurement technologies and their applications, and discusses the challenges in this field.
Lipid II as a target for antibiotics
Eefjan Breukink & Ben de Kruijff
p321 | doi:10.1038/nrd2004
Lipid II is an essential component of bacterial cell-wall biosynthesis, and as such is an attractive therapeutic target. Breukink and de Kruijff review the modes of action of compounds targeting Lipid II, and discuss their potential as treatments to combat bacterial infections.
Lipid phosphatases as drug discovery targets for type 2 diabetes
Dan F. Lazar & Alan R. Saltiel
p333 | doi:10.1038/nrd2007
The worldwide incidence of type 2 diabetes has reached epidemic proportions. More effective pharmaceutical options for the treatment of this devastating and costly disease are urgently needed. Dan Lazar and Alan Saltiel examine the exciting possibility that lipid phosphatases might provide a novel class of drug discovery targets for type 2 diabetes.
Cellular imaging in drug discovery
Paul Lang, Karen Yeow, Anthony Nichols & Alexander Scheer
p343 | doi:10.1038/nrd2008
Advances in cellular imaging technology mean that we can now measure multiple cellular parameters at high resolution at subcellular, single-cell or cell-population level. Lang et al. discuss the potential applications of this technology to drug R&D.
